Lipoprotein disorders classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
'''For patient information click [[Hyperlipidemia (patient information)|here]]'''
'''For patient information click [[Hyperlipidemia (patient information)|here]]'''
{{CMG}}
{{DiseaseDisorder infobox |
{{DiseaseDisorder infobox |
   Name        = Hyperlipidemia |
   Name        = Hyperlipidemia |
Line 7: Line 10:
}}
}}
{{SI}}
{{SI}}
{{CMG}}


==Overview==
==Overview==
Line 150: Line 152:


{{Metabolic pathology}}
{{Metabolic pathology}}
{{SIB}}


[[Category:Cardiology]]
[[Category:Cardiology]]

Revision as of 13:28, 29 October 2011

For patient information click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Template:DiseaseDisorder infobox

WikiDoc Resources for Lipoprotein disorders classification

Articles

Most recent articles on Lipoprotein disorders classification

Most cited articles on Lipoprotein disorders classification

Review articles on Lipoprotein disorders classification

Articles on Lipoprotein disorders classification in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Lipoprotein disorders classification

Images of Lipoprotein disorders classification

Photos of Lipoprotein disorders classification

Podcasts & MP3s on Lipoprotein disorders classification

Videos on Lipoprotein disorders classification

Evidence Based Medicine

Cochrane Collaboration on Lipoprotein disorders classification

Bandolier on Lipoprotein disorders classification

TRIP on Lipoprotein disorders classification

Clinical Trials

Ongoing Trials on Lipoprotein disorders classification at Clinical Trials.gov

Trial results on Lipoprotein disorders classification

Clinical Trials on Lipoprotein disorders classification at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lipoprotein disorders classification

NICE Guidance on Lipoprotein disorders classification

NHS PRODIGY Guidance

FDA on Lipoprotein disorders classification

CDC on Lipoprotein disorders classification

Books

Books on Lipoprotein disorders classification

News

Lipoprotein disorders classification in the news

Be alerted to news on Lipoprotein disorders classification

News trends on Lipoprotein disorders classification

Commentary

Blogs on Lipoprotein disorders classification

Definitions

Definitions of Lipoprotein disorders classification

Patient Resources / Community

Patient resources on Lipoprotein disorders classification

Discussion groups on Lipoprotein disorders classification

Patient Handouts on Lipoprotein disorders classification

Directions to Hospitals Treating Lipoprotein disorders classification

Risk calculators and risk factors for Lipoprotein disorders classification

Healthcare Provider Resources

Symptoms of Lipoprotein disorders classification

Causes & Risk Factors for Lipoprotein disorders classification

Diagnostic studies for Lipoprotein disorders classification

Treatment of Lipoprotein disorders classification

Continuing Medical Education (CME)

CME Programs on Lipoprotein disorders classification

International

Lipoprotein disorders classification en Espanol

Lipoprotein disorders classification en Francais

Business

Lipoprotein disorders classification in the Marketplace

Patents on Lipoprotein disorders classification

Experimental / Informatics

List of terms related to Lipoprotein disorders classification

Overview

Hyperlipidemias are classified according to the Fredrickson classification which is based on the pattern of lipoproteins on electrophoresis or ultracentrifugation.[1] It was later adopted by the World Health Organization (WHO). It does not directly account for HDL, and it does not distinguish among the different genes that may be partially responsible for some of these conditions. It remains a popular system of classification, but is considered dated by many.

Classification

Fredrickson classification of Hyperlipidemias
Hyperlipoproteinemia Synonyms Problems Labs description Treatment
Type I Buerger-Gruetz syndrome, Primary hyperlipoproteinaemia, or Familial hyperchylomicronemia Decreased lipoprotein lipase (LPL) or altered ApoC2 Elevated Chylomicrons Diet Control
Type IIa Polygenic hypercholesterolaemia or Familial hypercholesterolemia LDL receptor deficiency Elevated LDL only Bile Acid Sequestrants, Statins, Niacin
Type IIb Combined hyperlipidemia Decreased LDL receptor and Increased ApoB Elevated LDL and VLDL and Triglycerides Statins, Niacin, Gemfibrozil
Type III Familial Dysbetalipoproteinemia Defect in ApoE synthesis Increased IDL Drug of choice: Gemfibrozil
Type IV Endogenous Hyperlipemia Increased VLDL production and Decreased elimination Increased VLDL Drug of choice: Niacin
Type V Familial Hypertriglyceridemia Increased VLDL production and Decreased LPL Increased VLDL and Chylomicrons Niacin, Gemfibrozil

Hyperlipoproteinemia type I

This very rare form (also known as Buerger-Gruetz syndrome, primary hyperlipoproteinaemia, or familial hyperchylomicronemia) is due to a deficiency of lipoprotein lipase (LPL) or altered apolipoprotein C2, resulting in elevated chylomicrons, the particles that transfer fatty acids from the digestive tract to the liver. Lipoprotein lipase is also responsible for the initial breakdown of endogenously made triacylglycerides in the form of very low density lipoprotein (VLDL). As such, one would expect a defect in LPL to also result in elevated VLDL. Its prevalence is 0.1% of the population.

Hyperlipoproteinemia type II

Hyperlipoproteinemia type II, by far the most common form, is further classified into type IIa and type IIb, depending mainly on whether there is elevation in the triglyceride level in addition to LDL cholesterol.

Type IIa

This may be sporadic (due to dietary factors), polygenic, or truly familial as a result of a mutation either in the LDL receptor gene on chromosome 19 (0.2% of the population) or the ApoB gene (0.2%). The familial form is characterized by tendon xanthoma, xanthelasma and premature cardiovascular disease.

Type IIb

The high VLDL levels are due to overproduction of substrates, including triglycerides, acetyl CoA, and an increase in B-100 synthesis. They may also be caused by the decreased clearance of LDL. Prevalence in the population is 10%.

  • Familial combined hyperlipoproteinemia (FCH)
  • Secondary combined hyperlipoproteinemia (usually in the context of metabolic syndrome, for which it is a diagnostic criterion)

Treatment

While dietary modification is the initial approach, many patients require treatment with statins (HMG-CoA reductase inhibitors) to reduce cardiovascular risk. If the triglyceride level is markedly raised, fibrates may be preferable due to their beneficial effects. Combination treatment of statins and fibrates, while highly effective, causes a markedly increased risk of myopathy and rhabdomyolysis and is therefore only done under close supervision. Other agents commonly added to statins are ezetimibe, niacin and bile acid sequestrants. There is some evidence for benefit of plant sterol-containing products and ω3-fatty acids[2]

Hyperlipoproteinemia type III

This form is due to high chylomicrons and IDL (intermediate density lipoprotein). Also known as broad beta disease or dysbetalipoproteinemia, the most common cause for this form is the presence of ApoE E2/E2 genotype. It is due to cholesterol-rich VLDL (β-VLDL). Prevalence is 0.02% of the population.

Hyperlipoproteinemia type IV

This form is due to high triglycerides. It is also known as hypertriglyceridemia (or pure hypertriglyceridemia). According to the NCEP-ATPIII definition of high triglycerides (>200 mg/dl), prevalence is about 16% of adult population.[3]

Hyperlipoproteinemia type V

This type is very similar to type I, but with high VLDL in addition to chylomicrons.

It is also associated with glucose intolerance and hyperuricemia

Unclassified forms

Non-classified forms are extremely rare:

  • Hypo-alpha lipoproteinemia
  • Hypo-beta lipoproteinemia (prevalence 0.01-0.1%)

References

  1. Frederickson DS, Lee RS. A system for phenotyping hyperlipidemia. Circulation 1965;31:321-7. PMID 14262568.
  2. Thompson GR. Management of dyslipidaemia. Heart 2004;90:949-55. PMID 15253984.
  3. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106; page 3240

External links

Hyperlipoproteinemia OMIM GPnotebook WebMD Others
Type I Online Mendelian Inheritance in Man (OMIM) 238600 Template:GPnotebook . MeritCare
Type IIa Online Mendelian Inheritance in Man (OMIM) 144400 Template:GPnotebook . Merck
Type IIb Template:GPnotebook .
Type III . Template:GPnotebook WebMD Yahoo
Type IV Online Mendelian Inheritance in Man (OMIM) 144600 Template:GPnotebook WebMD Yahoo
Type V Online Mendelian Inheritance in Man (OMIM) 144600 Template:GPnotebook . .

Template:Metabolic pathology

de:Hyperlipoproteinämie he:היפרליפידמיה sv:Hyperlipidemi


Template:WikiDoc Sources